Cargando…
Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial
OBJECTIVE: To evaluate whether the addition of colchicine to standard treatment for COVID-19 results in better outcomes. DESIGN: We present the results of a randomised, double-blinded, placebo-controlled clinical trial of colchicine for the treatment of moderate to severe COVID-19, with 75 patients...
Autores principales: | Lopes, Maria Isabel, Bonjorno, Leticia P, Giannini, Marcela C, Amaral, Natalia B, Menezes, Pamella Indira, Dib, Saulo Musse, Gigante, Samara Libich, Benatti, Maira N, Rezek, Uebe C, Emrich-Filho, Laerte L, Sousa, Betania A A, Almeida, Sergio C L, Luppino Assad, Rodrigo, Veras, Flavio P, Schneider, Ayda, Rodrigues, Tamara S, Leiria, Luiz O S, Cunha, Larissa D, Alves-Filho, Jose C, Cunha, Thiago M, Arruda, Eurico, Miranda, Carlos H, Pazin-Filho, Antonio, Auxiliadora-Martins, Maria, Borges, Marcos C, Fonseca, Benedito A L, Bollela, Valdes R, Del-Ben, Cristina M, Cunha, Fernando Q, Zamboni, Dario S, Santana, Rodrigo C, Vilar, Fernando C, Louzada-Junior, Paulo, Oliveira, Rene D R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868202/ https://www.ncbi.nlm.nih.gov/pubmed/33542047 http://dx.doi.org/10.1136/rmdopen-2020-001455 |
Ejemplares similares
-
Colchicine reduces the activation of NLRP3 inflammasome in COVID-19 patients
por: Amaral, N. B., et al.
Publicado: (2023) -
SARS-CoV-2–triggered neutrophil extracellular traps mediate COVID-19 pathology
por: Veras, Flavio Protasio, et al.
Publicado: (2020) -
Infection of human lymphomononuclear cells by SARS-CoV-2
por: Pontelli, Marjorie C, et al.
Publicado: (2020) -
Fructose 1,6-bisphosphate, a high-energy intermediate of glycolysis, attenuates experimental arthritis by activating anti-inflammatory adenosinergic pathway
por: Veras, Flávio P., et al.
Publicado: (2015) -
Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients
por: Rodrigues, Tamara S., et al.
Publicado: (2020)